The director of the multiple sclerosis research unit at Ottawa Hospital spoke about the importance of long-term efficacy studies.
"The caveat is that those who are around for the count and have stayed on the medicine and are obviously doing well, you're biasing your population to that group and I don't think we can really say anything established about the efficacy, and this goes for any molecule including teriflunomide."
At the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2019 Forum held in Dallas, Texas, Mark Freedman, MD, spoke about the importance of long-term efficacy studies.
The professor of neurology at the University of Ottawa, a senior scientist at the University of Ottawa, Ottawa Hospital Research Institute, and director of the multiple sclerosis research unit at the Ottawa Hospital general campus, explained that when speaking about efficacy, the results should be accepted with a grain of salt.
To provide additional insight, Freedman spoke with NeurologyLive in an interview at the meeting and concluded that nothing established can be said about the efficacy for any molecule.
Related Content:Americas Committee for Treatment and Research in Multiple Sclerosis | Conferences | News | Multiple Sclerosis